The stock price of Biohaven Ltd (NYSE: BHVN) has jumped by 0.77 compared to previous close of 19.51. Despite this, the company has seen a gain of 3.36% in its stock price over the last five trading days. prnewswire.com reported 2025-05-14 that – Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. – Troriluzole has been granted Fast-Track, Orphan Drug Designation (ODD) and Priority Review from the FDA.
Is It Worth Investing in Biohaven Ltd (NYSE: BHVN) Right Now?
Company’s 36-month beta value is 3.88.Analysts have differing opinions on the stock, with 11 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BHVN is 88.50M, and currently, short sellers hold a 8.82% ratio of that floaft. The average trading volume of BHVN on May 15, 2025 was 1.60M shares.
BHVN’s Market Performance
BHVN’s stock has seen a 3.36% increase for the week, with a 6.21% rise in the past month and a -53.32% fall in the past quarter. The volatility ratio for the week is 9.48%, and the volatility levels for the past 30 days are at 9.53% for Biohaven Ltd The simple moving average for the last 20 days is -5.82% for BHVN’s stock, with a simple moving average of -47.73% for the last 200 days.
Analysts’ Opinion of BHVN
Many brokerage firms have already submitted their reports for BHVN stocks, with Deutsche Bank repeating the rating for BHVN by listing it as a “Buy.” The predicted price for BHVN in the upcoming period, according to Deutsche Bank is $65 based on the research report published on February 11, 2025 of the current year 2025.
Jefferies, on the other hand, stated in their research note that they expect to see BHVN reach a price target of $57. The rating they have provided for BHVN stocks is “Buy” according to the report published on September 16th, 2024.
Bernstein gave a rating of “Outperform” to BHVN, setting the target price at $55 in the report published on September 04th of the previous year.
BHVN Trading at -16.46% from the 50-Day Moving Average
After a stumble in the market that brought BHVN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.70% of loss for the given period.
Volatility was left at 9.53%, however, over the last 30 days, the volatility rate increased by 9.48%, as shares surge +5.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -37.33% lower at present.
During the last 5 trading sessions, BHVN rose by +3.36%, which changed the moving average for the period of 200-days by -52.29% in comparison to the 20-day moving average, which settled at $20.87. In addition, Biohaven Ltd saw -47.36% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BHVN starting from CHILDS JOHN W, who purchase 32,700 shares at the price of $30.47 back on Mar 04 ’25. After this action, CHILDS JOHN W now owns 2,320,571 shares of Biohaven Ltd, valued at $996,238 using the latest closing price.
CHILDS JOHN W, the Director of Biohaven Ltd, purchase 29,000 shares at $35.94 during a trade that took place back on Dec 30 ’24, which means that CHILDS JOHN W is holding 2,368,741 shares at $1,042,393 based on the most recent closing price.
Stock Fundamentals for BHVN
The total capital return value is set at -3.13. Equity return is now at value -316.82, with -202.53 for asset returns.
Based on Biohaven Ltd (BHVN), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -20.94.
Currently, EBITDA for the company is -841.76 million with net debt to EBITDA at 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.33.
Conclusion
In a nutshell, Biohaven Ltd (BHVN) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
